Balstilimab
- Generic Name
- Balstilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2148321-77-9
- Unique Ingredient Identifier
- 1Q2QT5M7EO
- Associated Conditions
- -
- Associated Therapies
- -
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
Phase 2
Recruiting
- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Michael B. Atkins, MD
- Target Recruit Count
- 120
- Registration Number
- NCT05928806
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath